title: A case of amyloidosis associated with diphenylhydantoin therapy.
abstract: Prolonged administration of diphenylhydantoin (DPH) has been implicated as a possible etiologic factor in immunological aberrations and lymphoproliferative disorders. Diphenylhydantoin may account for the increase in susceptibility to lymphoproliferative diseases, as a result of its immunosuppressive effect. We report a case of amyloidosis with monoclonal gammopathy which developed during DPH treatment, without multiple myeloma or lymphoproliferative disorders. The association between DPH and monoclonal gammopathy is very rare, and such a case of amyloidosis associated with DPH has not been reported previously. DPH, however, may have played a role in the development of monoclonal gammopathy, which was the precursor of amyloid protein.
authors.affiliation: Department of Medicine, Kawasaki Medical School, Okayama, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Nomura
authors.forename: G
authors.initials: G
authors.lastname: Osawa
authors.forename: T
authors.initials: T
authors.lastname: Sato
authors.forename: T
authors.initials: T
authors.lastname: Ishimatsu
authors.forename: T
authors.initials: T
authors.lastname: Shindo
authors.forename: H
authors.initials: H
authors.lastname: Hirano
mesh_terms: D000368:Aged; D000686:Amyloidosis / Q000139:chemically induced* / Q000473:pathology; D004834:Epilepsy, Post-Traumatic / Q000188:drug therapy; D005260:Female; D006801:Humans; D006942:Hypergammaglobulinemia / Q000139:chemically induced; D007678:Kidney Glomerulus / Q000648:ultrastructure; D008297:Male; D008875:Middle Aged; D009404:Nephrotic Syndrome / Q000139:chemically induced; D010672:Phenytoin / Q000009:adverse effects*
chemical_list: D010672:Phenytoin